# WIA-BIO-006 — Phase 1: Data Format

> Tissue-engineering canonical Phase 1: scaffold + bioink + architecture + cell-source + QC envelopes.

# WIA-BIO-006: Tissue Engineering Specification v1.0

> **Standard ID:** WIA-BIO-006
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Biomedical Engineering Research Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Scaffold Materials and Design](#2-scaffold-materials-and-design)
3. [3D Bioprinting Protocols](#3-3d-bioprinting-protocols)
4. [Bioreactor Systems](#4-bioreactor-systems)
5. [Vascularization Strategies](#5-vascularization-strategies)
6. [Cell Culture and Seeding](#6-cell-culture-and-seeding)
7. [Quality Testing Standards](#7-quality-testing-standards)
8. [Regulatory Requirements](#8-regulatory-requirements)
9. [Implementation Guidelines](#9-implementation-guidelines)
10. [References](#10-references)

---


## 1. Introduction

### 1.1 Purpose

This specification defines the comprehensive framework for tissue engineering, covering scaffold design, biofabrication, cell culture, and quality assurance for regenerative medicine applications.

### 1.2 Scope

The standard covers:
- Natural, synthetic, and hybrid biomaterial scaffolds
- 3D bioprinting techniques and protocols
- Bioreactor design and operation
- Vascularization and perfusion strategies
- Quality control and regulatory compliance

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - This standard aims to advance tissue engineering to restore health, save lives, and improve quality of life through regenerative medicine accessible to all.

### 1.4 Terminology

- **Scaffold**: Three-dimensional structure that supports cell attachment and tissue formation
- **Bioprinting**: Additive manufacturing process using living cells
- **Bioreactor**: Device that provides controlled environment for tissue culture
- **ECM**: Extracellular matrix - natural scaffold produced by cells
- **Decellularization**: Process of removing cells while preserving ECM structure

---



## 2. Scaffold Materials and Design

### 2.1 Natural Biomaterials

#### 2.1.1 Collagen

**Properties**:
```
Young's Modulus: 1-10 MPa
Degradation: 2-8 weeks
Porosity: 70-95%
Cell Adhesion: Excellent (RGD domains)
```

**Applications**: Skin, bone, cartilage, vascular grafts

**Preparation**:
1. Extract from animal sources (bovine, porcine)
2. Purify via salt precipitation
3. Neutralize to pH 7.4
4. Cross-link if needed (EDC, genipin)

#### 2.1.2 Gelatin

**Properties**:
```
Young's Modulus: 0.1-1 MPa
Degradation: 1-4 weeks
Gelation Temperature: 20-30°C
Biocompatibility: Excellent
```

**Advantages**:
- Low immunogenicity
- Thermoresponsive gelation
- Cost-effective
- Easy to process

#### 2.1.3 Chitosan

**Properties**:
```
Young's Modulus: 1-2 GPa
Degradation: 4-12 weeks
pH-responsive: Yes
Antimicrobial: Yes
```

**Processing**:
- Dissolve in acidic solution (pH 5-6)
- Freeze-dry for porous structures
- Can be blended with other polymers

#### 2.1.4 Alginate

**Properties**:
```
Ionic cross-linking: Ca²⁺, Ba²⁺
Gelation: Instantaneous
Young's Modulus: 10-100 kPa
Biocompatibility: Good
```

### 2.2 Synthetic Biomaterials

#### 2.2.1 Polycaprolactone (PCL)

**Properties**:
```
Young's Modulus: 200-400 MPa
Degradation: 6-24 months
Melting Point: 60°C
Hydrophobicity: High
```

**Advantages**:
- FDA approved
- Excellent mechanical properties
- Slow degradation (matches bone healing)
- Easy to process (electrospinning, 3D printing)

#### 2.2.2 Polylactic Acid (PLA)

**Properties**:
```
Young's Modulus: 2-4 GPa
Degradation: 6-12 months
Glass Transition: 60-65°C
Crystallinity: 37%
```

**Applications**: Bone, cartilage, temporary implants

#### 2.2.3 Polyglycolic Acid (PGA)

**Properties**:
```
Young's Modulus: 7 GPa
Degradation: 2-4 weeks
Highly crystalline: 45-55%
Water soluble: Yes
```

**Uses**: Fast-degrading applications, sutures

### 2.3 Hybrid Scaffolds

#### 2.3.1 PCL-Collagen Composite

```
Composition: 70% PCL + 30% Collagen
Young's Modulus: 50-150 MPa
Porosity: 65-80%
Degradation: 3-6 months
```

**Benefits**:
- Combines mechanical strength (PCL) with bioactivity (collagen)
- Tunable degradation rate
- Enhanced cell adhesion

#### 2.3.2 Gelatin-Alginate Blend

```
Ratio: 1:1 to 3:1 (gelatin:alginate)
Gelation: Dual (thermal + ionic)
Mechanical Strength: 10-50 kPa
Injectable: Yes
```

### 2.4 Scaffold Architecture

#### 2.4.1 Porosity Design

```
P = (1 - ρ_apparent / ρ_material) × 100%
```

Where:
- `P` = Porosity (%)
- `ρ_apparent` = Apparent density (g/cm³)
- `ρ_material` = Material density (g/cm³)

**Recommended ranges**:
- Bone: 60-80%
- Cartilage: 70-85%
- Skin: 80-95%
- Liver: 85-90%

#### 2.4.2 Pore Size

```
d_pore = (6 × V_void / S_pore)
```

Where:
- `d_pore` = Average pore diameter (μm)
- `V_void` = Void volume (mm³)
- `S_pore` = Pore surface area (mm²)

**Optimal pore sizes**:
- Osteoblasts: 100-400 μm
- Fibroblasts: 50-150 μm
- Endothelial cells: 30-100 μm
- Hepatocytes: 20-50 μm

#### 2.4.3 Interconnectivity

Minimum interconnectivity: **90%**

```
I = (N_connected / N_total) × 100%
```

Where:
- `I` = Interconnectivity (%)
- `N_connected` = Connected pores
- `N_total` = Total pores

### 2.5 Mechanical Properties

#### 2.5.1 Compression Testing

```
σ = F / A₀
ε = ΔL / L₀
E = σ / ε
```

Where:
- `σ` = Compressive stress (Pa)
- `F` = Applied force (N)
- `A₀` = Initial cross-sectional area (m²)
- `ε` = Strain (dimensionless)
- `ΔL` = Change in length (m)
- `L₀` = Initial length (m)
- `E` = Young's modulus (Pa)

#### 2.5.2 Tissue-Specific Requirements

| Tissue | Young's Modulus | Ultimate Strength | Strain at Failure |
|--------|----------------|-------------------|-------------------|
| Bone | 10-20 GPa | 100-200 MPa | 1-3% |
| Cartilage | 0.5-2 MPa | 5-25 MPa | 10-20% |
| Skin | 0.1-2 MPa | 1-20 MPa | 30-70% |
| Liver | 0.5-1 kPa | 1-5 kPa | 20-40% |
| Cardiac | 10-50 kPa | 10-100 kPa | 15-30% |

---




---

## A.1 Scaffold-record envelope

The Phase 1 envelope groups scaffold records by material family (natural — collagen, gelatin, chitosan, alginate, fibrin, hyaluronic acid, silk fibroin; synthetic — PCL, PLA, PGA, PLGA, PEG, polyurethane; hybrid composites; decellularized extracellular matrix) with the canonical fields: chemical formula or polymer ratio, mean Young's modulus in Pa, ultimate strength, strain at failure, porosity in %, mean pore diameter in micrometres, interconnectivity in %, degradation half-life, and the cross-link chemistry (EDC, genipin, UV-initiated photocrosslinking, ionic, thermal). Material data follows the reporting conventions of ASTM F2150 (characterisation of biomaterial scaffolds) and ISO 13314 (compression test for porous metals — applied analogously for polymeric scaffolds).

## A.2 Bioink-formulation envelope

A bioink record MUST list polymer base, polymer concentration in % (w/v), cross-linker (Ca2+, light at 365/405 nm, temperature, enzymatic), cell type, cell density in cells/mL, growth-factor cocktail (VEGF, BMP, FGF, TGF-beta, IGF-1) in ng/mL, viscosity at the print shear rate in mPa·s, storage modulus G' in Pa, loss modulus G'' in Pa, and the rheological profile (shear-thinning index n, yield stress). Bioinks intended for FDA submission MUST cross-reference the Phase 4 §A.3 regulatory envelope so downstream consumers can see the regulatory pathway from one record.

## A.3 Architecture descriptor

The architecture descriptor enumerates pore-network topology (gyroid, Schwarz P, Schoen IWP, octet truss, stochastic foam, hierarchical micro/macro), pore-size distribution (mean, standard deviation, D10/D50/D90 percentiles), surface-area-to-volume ratio, fibre diameter for electrospun scaffolds, fibre alignment (anisotropy index), and the mechanical anisotropy axes. Tissue-specific architectures cross-reference the target-tissue envelope at Phase 3 §A.5 so downstream consumers can verify the architecture-to-tissue match.

## A.4 Cell-source descriptor

Every cell-source envelope carries: source category (primary, established cell line, stem cell — ESC/MSC/iPSC/HSC), donor metadata (ID, age, sex, ethnicity where consented, lot number), passage number, viability at thaw in %, sterility status (mycoplasma-free per USP <63>; endotoxin per USP <85> at < 0.5 EU/mL), karyotype (for stem cells), differentiation marker panel, and the chain-of-custody hash that ties the cells to the contributing institution's signing key.

## A.5 Quality-test descriptor

Quality-test descriptors carry test category (sterility per USP <71>, endotoxin per USP <85>, cytotoxicity per ISO 10993-5, mechanical per ASTM F2150, biocompatibility per ISO 10993-6 implantation, immunogenicity), measurement method, instrument identifier, calibration record reference, raw measurement payload (or link to the data store), processed result, pass/fail flag against the standard's acceptance criteria, and the analyst signature. Reports MUST cite the controlling ISO/ASTM/USP document and MUST include a measurement-uncertainty budget per ISO/IEC Guide 98-3 (GUM).


---

## Z.1 Glossary, conformance, governance

A companion glossary at `https://wiastandards.com/tissue-engineering/glossary/`
expands every term used throughout this Phase. The conformance
test suite at `https://github.com/WIA-Official/wia-tissue-engineering-conformance`
walks every endpoint and protocol exchange. The reference container
at `wia/tissue-engineering-host:1.0.0` ships every tissue-engineering envelope and
endpoint with mock data so integrators can exercise the contract
before wiring real backends. The companion CLI at
`cli/tissue-engineering.sh` ships sample envelope generators with no
dependencies beyond `jq` and POSIX shell.

## Z.2 Cross-standard composition (recap)

This Phase composes with WIA-OMNI-API for credential storage,
WIA-AIR-SHIELD for runtime trust list, WIA-SOCIAL Phase 3 §5 for
federation handshake, WIA-INTENT for workload intent declaration,
and (where personal data is processed) WIA Secure Enclave for
sealed-data envelopes. The composition lets one host running
multiple WIA family standards reuse one identity, one signing key
chain, and one audit transport rather than maintaining N parallel
implementations.

## Z.3 Implementation runbook

A first implementation typically follows: stand up the reference
container; run the conformance suite against it end-to-end;
replace the mock backend with a real backend one endpoint at a
time; wire audit-log replication out to the operations sink;
onboard a single trusted peer for federation; expand to multiple
peers; promote to production with the warning-envelope subscription
enabled and the runbook in §Z.5 followed.

## Z.4 Backwards-compatibility promise

Within the 1.x line, every Phase 1 envelope shape, every Phase 2
endpoint, and every Phase 3 protocol exchange MUST remain reachable
and MUST continue to honour the documented status codes and content
shapes. Hosts MAY add optional fields and new envelopes; hosts MUST
NOT remove existing ones. Breaking changes ride a major version
bump with a 12-month deprecation window per IETF RFC 8594 and 9745
and require a two-thirds Committee vote.

## Z.5 Closing implementer note

This Phase fits inside the WIA Standards four-Phase architecture:
Phase 1 envelopes are the wire-format contract; Phase 2 surfaces
them through HTTPS; Phase 3 wraps them in protocol exchanges that
cross trust boundaries; Phase 4 integrates with the broader
ecosystem. Tissue-engineering deployments that follow this layering
inherit the per-Phase conformance gates and the cross-standard
composition behaviour described in Z.2.

弘益人間 — Benefit All Humanity.
